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Background: The presence of basidiomycetous (BM) fungi in induced sputum is an important clinical finding in
chronic idiopathic cough (CIC). However, the efficacy of anti-fungal therapy for CIC has not been evaluated.
Methods: We selected 10 patients with CIC and carried out allergological examinations for Bjerkandera adusta, a
BM fungus that has been shown to enhance cough severity. The efficacy of low-dose itraconazole (ITCZ) therapy
(50 mg/day) for 14 days as an adjunctive therapy was estimated with use of Cough Visual Analog Scale (Cough
VAS) and the Japanese version of the Leicester Cough Questionnaire (J-LCQ). We evaluated whether there was a
recognizable clinical or allergological pattern that could predict the efficacy of ITCZ therapy in CIC patients.
Results: Significant changes in Cough VAS and minimal important difference in domains of the J-LCQ were
observed in 3 and 5 CIC patients, respectively. The Δ cough scale was correlated with changes in domains of the
J-LCQ (total (r = –0.73, P < 0.05), psychological (r = –0.73, P < 0.05), and social (r = –0.71, P < 0.05), respectively. There
were significant differences in the change in total score (P < 0.05) and in the domain of social (P < 0.05) and Δ
cough scale (P < 0.05) between positive and negative results of immediate skin test for B. adusta. Positive results for
improvement of cough-related laryngeal sensation which was represented as a sensation of mucus in the throat
(SMIT) were observed in 6 patients in the BM colonization-positive group (85.7%) and none in the BM
colonization-negative group (0%). There was a significant difference in the positive ratio for improvement of SMIT
between the two groups.
Conclusions: At present, it is not possible to conclude whether ITCZ therapy provides sufficient relief in CIC
patients. However, this study suggested both the possible applicability of low-dose ITCZ therapy for treatment of
CIC patients with regard to BM allergy and the necessity of development of a new assessment questionnaire for
cough-related laryngeal sensations.
Trial registration: UMIN-CTR (reference number R000005872; UMIN000004933).
Keywords: A sensation of mucus in the throat, Bjerkandera adusta, Chronic idiopathic cough, Fungus-associated
chronic cough, The Japanese version of LCQBackground
Despite extensive diagnostic evaluation and numerous
treatment guidelines [1-3], a subgroup of chronic cough
patients in whom a diagnosis cannot be made even after
thorough systematic investigation remain troubled by
chronic idiopathic cough (CIC) [4,5], defined as an un-
controllable cough that is difficult to treat. Therefore,
there is a great deal of research interest [6,7] regarding* Correspondence: saiseikh@po3.nsknet.or.jp
1The Division of Pulmonary Medicine, Ishikawa-ken Saiseikai Kanazawa
Hospital, Ni-13-6 Akatsuchi-machi, Kanazawa 920-0353, Japan
Full list of author information is available at the end of the article
© 2013 Ogawa et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe identification of novel antitussive drugs [8-11] and
the establishment of novel therapeutic strategies.
We recently encountered a cluster of patients with al-
lergic fungal cough (AFC), which is intractable and is
characterized by sensitization to Bjerkandera adusta [9],
among a new clinical disease concept termed fungus-
associated chronic cough (FACC) [10] with the following
manifestations: (1) chronic cough; (2) the presence of
environmental fungi, particularly basidiomycetous (BM)
fungi, in the sputum; and (3) good clinical response to
antifungal drugs. Thus antifungal drugs have provided a
new treatment strategy for chronic intractable coughLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ever, the efficacy of anti-fungal therapy for CIC has not
been evaluated yet.
As the presence of BM fungi in induced sputum has
been shown to be an important factor in distinguishing
the clinical manifestations of CIC from those of non-
CIC [13], we describe here our clinical experience in 10
CIC patients treated with low-dose itraconazole (ITCZ).
We attempted to clarify the problems raised in the
process of evaluating the clinical efficacy of low-dose
ITCZ, especially with regard to both colonization of BM




Strains and DNA preparation
The sputum samples obtained from the patients with CIC
patients were cultured on Sabouraud’s dextrose agar
(SDA) containing chloramphenicol. The morphological
features of the strains were observed with the slide culture
method (30°C for 2~3 weeks). When the white colonies
grew widely on SDA; the resulting colonies were moved
onto CHROMagarW Candida spread with micafungin so-
dium (FunguardW, 30 μ/plate) [11].
Allergological tests
Preparation of the antigenic solution
The antigens Aspergillus, Alternaria, and Candida were
commercially available (Torii Pharmacy, Tokyo, Japan).
One liter of Sabouraud dextrose broth in 3 L flasks was
sterilized by autoclaving at 121°C for 20 min. Five millili-
ters of B. adusta (NBRC 4983) or Schizophyllum
commune spore suspension (105 spores/ml) in sterile
physiological saline from 14 day-old SDA culture was
used to inoculate the flask. The flasks were shaken at
150 rpm in a 25°C rotary shaker incubator. The super-
natant was then dialyzed against 5 mM ammonium
bicarbonate and lyophilized.
Intradermal skin test
An antigenic solution (polysaccharide) was injected intra-
dermally with a tuberculin syringe (0.02 mL, 1 mg/mL) to
assess the skin response to the solution. The results were
judged to be positive when the longer axis of the flare
exceeded 9 mm and/or ≥ 3 mm above negative control at
15 min (immediate phase), and 10 mm at 8 h (late phase)
after the injection.
Serological test
House-dust, mite, Aspergillus, Alternaria, Penicillium,
Cladosporium, Candida Trichophyton; Allergen-specific
IgE antibodies were detected using a capsulated hydro-
philic carrier polymer radioallergosorbent test fluoroenzymeimmunoassay (Phadia, Uppsala, Sweden) at an external la-
boratory (SRL, Tokyo, Japan).Lymphocyte stimulation test
The lymphocyte stimulation test (LST) [14] was per-
formed using the antigenic solution with the Lympho-
prep system. The results were considered positive when
the magnitude of the response to B.adusta was beyond
200% in comparison to the controls using PHA.Diagnostic criteria of CIC
According to the Japanese Cough Research Society [1],
Japanese Respiratory Society [2], and the American College
of Chest Physicians evidence-based practice guidelines [3],
the cause of chronic cough in each patient was diagnosed
based on a questionnaire, blood examination findings,
chest and sinus X-rays, induced-sputum examination,
pulmonary function tests [15], test for cough reflex sensi-
tivity to inhaled capsaicin [16], bronchial reversibility in
response to bronchodilators, bronchial responsiveness to
methacholine, and the efficacy of individual cause-specific
treatments. The capsaicin cough threshold was defined as
the lowest concentration of inhaled capsaicin eliciting five
or more coughs (C5). Capsaicin reflex sensitivity was
judged to be increased when capsaicin concentration
eliciting five or more coughs (C5) was < 3.9 μM in males
or < 0.98 μM in females [17]. Positive bronchial reversibil-
ity was defined as percentage increase in FEV1 > 12% and
absolute increase in FEV1 > 200 mL. The non-specific
bronchial responsiveness to methacholine was assessed
according to the method described by Cockcroft et al. [18].
The results were expressed as the provocation concentra-
tion (mg/mL) required to cause a 20% or more fall from
the baseline FEV1 (respiratory threshold of methacholine;
RT-Meth).
The specific treatments given before the diagnosis of
CIC was made were as follows: Suspected cough variant
asthma [19] was treated in the first instance with β2-
agonists (a combination of oral 40 μg/day clenbuterol and
200 μg salbutamol inhalation at bedtime and on demand).
If this proved insufficient, treatment was stepped up
according to the guidelines on the treatment of asthma.
Suspected atopic cough [20], i.e., bronchodilator-resistant
cough (eosinophilic tracheobronchitis with cough hyper-
sensitivity), was treated with histamine H1 antagonists
and inhaled corticosteroids (a combination of 10 mg/day
cetrizine hydrochloride and 400–800 μg/day fluticasone
propionate). Suspected sinobronchial syndrome [21] was
treated with clarithromycin (oral 200 mg/day). Suspected
gastro-oesophageal reflux [22] was treated with a high
dose of proton-pomp inhibitors. The duration of each
treatment was a minimum of 3 months.
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symptoms
Cough Visual Analog Scale (Cough VAS)
A subset of subjects marked a 100-mm linear VAS to
indicate severity of their cough from “no cough” to
“worst cough.” The efficacy of the treatment was evalu-
ated based on the change in the cough scale before and
after treatment (Δ cough scale), and a change in Δ
cough scale by more than 15 mm was taken to be sig-
nificant [23].
Cough-related quality of life
The Leicester Cough Questionnaire (LCQ) [24] is a
valid, reproducible, responsive, self-reported, cough-
specific health status measure. The Japanese version of
LCQ (J-LCQ) was adapted for Japanese conditions fol-
lowing a forward-backward translation procedure [25].
The LCQ total score ranges from 3 to 21 and from 1 to
7 for physical, psychological and social domains; a higher
score indicates a better health-related quality of life. The
mean (standard deviation) minimal important difference
(MID) of the LCQ corresponding to a small change
in the four Global Rating of Change Questionnaires
(GRCQ) score was 1.3. The MIDs for domains were
as follows: physical 0.2, social 0.2, and psychological
0.8 [26].
Protocol
Ten patients diagnosed with CIC and treated for
more than 2 years were selected for this study from 1
February to 30 April 2011. Allergological examina-
tions were performed using an antigenic solution of
B. adusta. The patients received a low dose of ITCZ
(50 mg/day) for 14 days as adjunctive therapy. The effi-
cacy of the drug was estimated with use of Cough VAS
and the J-LCQ.
IRB approval
This selected, open, single-arm, prospective trial was
approved by the institutional review board of Saiseikai
Kanazawa Hospital (reference number 2011007) and ap-
proval for the study was obtained from UMIN-CTR
(reference number R000005872; UMIN000004933). A
written informed consent was obtained from each pa-
tient prior to enrollment in the study.
Statistical analysis
Variables are expressed as the mean (SD) unless other-
wise stated. For comparison of multiple groups, analysis
of variance (ANOVA) followed by Fisher’s protected
least significant difference post hoc test was used for
parametric data, when a significant difference was found.
For nonparametric data, the Kruskal–Wallis test followed
by the Mann–Whitney U test was applied instead. The χ2test was used for categorical data. Analyses were per-
formed using the SPSS statistical software package. In all
analyses, P < 0.05 was taken to indicate statistical
significance.
Results
Ten patients with CIC had a median age of 65.0 (range,
47–71) years, and 70.0% were female. Chest and sinus
radiographs were normal in all patients. Based on their
clinical histories, the duration of cough ranged from 27
to 70 months. None of the patients complained of short-
ness of breath or wheezing and none had post-nasal drip
or sinobronchial syndrome that could be responsible for
the cough. The mean white blood cell count was 5365.0 ±
1423.6 (SD) μL with 1.8% ± 1.5% (SD) eosinophils in per-
ipheral blood. The total serum IgE levels were found to be
elevated in 2 patients and mean level was 132.8 ±
217.9 IU/mL (mean ± SEM). Mean lung functions were as
follows: FVC 114.1% ± 21.5% of predicted, FEV1 117.5% ±
26.5% of predicted, and FEV1/FVC ratio 79.7% ± 4.6%. The
mean bronchodilator reversibility was 2.1% ± 2.8% (SD).
Chronic airflow limitation, defined as the ratio of forced
expiratory volume in 1 s (FEV1) to the forced vital capacity
(FVC), i.e., FEV1/FVC < 0.7 and FEV1 < 80% of the pre-
dicted value, and bronchial reversibility in response to
bronchodilators were not observed. Bronchial responsive-
ness to methacholine was heightened in one patient.
Cough reflex sensitivity, as assessed by estimation of the
capsaicin cough threshold, was increased in 3 patients
(Table 1).
Positive results of sputum culture for BM, Aspergillus
fumigatus, Aspergillus niger, and Candida were detected
in 7, 3, 3, and 2 patients, respectively.
The allergological findings of the 10 patients are sum-
marized in Table 2. Eosinophilia in the induced sputum
was observed in 1 patient. Although no immediate cuta-
neous reactions to Aspergillus or Alternaria were
observed, positive results for immediate cutaneous reac-
tion to Candida, B. adusta, and S. commune were
observed in 4, 6, and 1 patient, respectively. In addition,
positive results for late cutaneous reaction to Candida,
B. adusta, and S. commune were observed in 1, 5, and 1
patient, respectively. Specific IgE for house-dust and
mites were positive only in Patient No. 1. Positive ratios
on LST against B. adusta were observed in 6 patients.
The efficacies of low-dose ITCZ therapy in 10 patients
are summarized in Table 3. Significant changes in Δ
cough scale or MID in domains of the J-LCQ were
observed in 3 and 5 patients, respectively. The Δ
cough scale was correlated with changes in some
domains of the J-LCQ [total (r = –0.73, P < 0.05),
psychological (r = –0.73, P < 0.05), and social (r = –0.71,
P < 0.05)], but not with changes in the physical domain
or in capsaicin cough threshold. There were significant
Table 2 Allergological findings of the 10 patients with CIC
Case 1 2 3 4 5 6 7 8 9 10
Fungal culture BM, An Can, Af, BM Can BM BM none Af, BM BM, An BM Af, An
Eo. In sputum 0% 5% 1% 0% 0% 0% 0% 0% 1% 0%
Skin tests
Aspergillus imme 4x4 3x3 2x2/0x0 0x0/0x0 5x6 2x2/0x0 0x0/0x0 2x2/0x0 4x4 4x4
late 4x4 4x4 2x3 5x6 3x3 0x0/0x0 5x5 0x0 3x3
Alternaria imme 2x2 3x3 4x4 0x0/0x0 2x2 3x3/0x0 0x0/0x0 0x0/3x3 5x5 ND
Candida imme 5x5 10x10/22x22 0x0/0x0 12x12/16x14 9x10/40x31 4x4/0x0 8x8/28x30 0x0/3x3 ND ND
late 4x4 9x6 5x5 6x6 3x3/8x8 10x10 0x0/3x3
B.adusta imme 5x6/25x25 4x4/0x0 6x6/0x0 0x0/12x8 0x0/10x8 2x2/0x0 6x6/26x24 0x0/6x6 6x6/16x18 0x0/10x10
late 5x5 4x4/10x8 9x8 7x7/10x10 15x14 7x7 15x15 10x10 4x5 4x4
S. commune imme 0x0/0x0 2x2/0x0 5x5/0x0 0x0/0x0 4x4 4x4/0x0 0x0/0x0 0x0/0x0 4x4 4x9
late 0x0/9x9 8x5 8x7 0x0/0x0 7x6 3x3 10x10 3x3 9x9 9x9
Specific IgE
House-dust 1.86 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34>
Mite 2.69 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34>
Aspergillus 0.34> 0.34> 0.34> 0.34> 0.4 0.34> 0.34> 0.34> 0.34> 0.34>
Alternaria 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34>
Cladosporium 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34>
Penicillium 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34>
Candida 0.34> 0.34> 0.34> 0.34> 7.05 0.34> 0.34> 0.34> 0.34> 0.34>
Trichophyton 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34> 0.34>
LST negative positive positive positive positive negative positive positive ND ND
Eo.= eosinophil.
BM; basidiomycetous fungi, Can; Candida, Af; Aspergillus fumigatus, An; Aspergillus niger.
imme; immediate phase response, late; late phase response.
LST; lymphocyte stimulation tests, ND; not done.
Table 1 Characteristics of the 10 patients with CIC
Case 1 2 3 4 5 6 7 8 9 10
Age (yr) 63 70 68 69 67 55 62 71 47 63
Gender M F M F F M F F F F
Smoking ex-smoker never never never never never never never never never
Duration (Month) 49 68 66 70 44 64 48 27 41 62
WBC 4350 5800 8100 5600 5900 6600 4000 4900 3000 5400
Eo (%) 2.4 5.2 1.1 1.7 1.1 0 1.4 1 3.2 1.7
IgE (IU/ml) 179 20 97 119 734 75.5 16 38 20 29
FVC 2.78(81.0) 2.64(118.9) 4.67(137.0) 2.46(108.4) 3.46(149.8) 3.70(98.9) 2.94(126.2) 2.69(123.4) 2.95(110.5) 2.17(87.1)
FEV1 2.13(80.1) 1.90(118.7) 3.62(138.2) 1.93(114.9) 2.69(152.0) 3.07(96.5) 2.56(143.0) 2.20(144.7) 2.53(106.3) 1.67(80.7)
FEV1/FVC (%) 76.6 72 77.5 78.5 77.7 83 87.1 81.8 85.8 77
Reversibility (%) 1.2 2.6 −3.6 5.7 3.7 1.3 0.4 0.9 5.9 2.4
Rt-Meth (mg/mL) 20000< 20000< 20000< 20000< 20000< 20000< 5000 20000< 20000< 20000<
Cough (μM) 0.98 31.3 62.5 31.3 1.95 15.6 3.91 0.49 0.49 1.95
Eo: Eosinophil.
FEV1: forced expiratory volume in 1 s.
FEV1%: the ratio of forced expiratory volume in is (FEV1) to forced vital capacity (FVC).
RT-Meth: respiratory threshold of methacholine (mg/ml) required to cause a 20% or more fall in FEV1 from the baseline value.
Cough: The capsaicin cough threshold (C5) was defined as the lowest concentration of inhaled capsaicin eliciting five or more coughs.
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Table 3 Changes in domains of J-LCQ in 10 patients with CIC pre- and post-low-dose ITCZ therapy
pre- post- pre- post- pre- post- pre- post- pre- post-
Case 1 2 3 4 5
J-LCQ
total 14.29 15.92 1.63 * 16.13 16.61 0.48 18.63 17.61 −1.02 14.84 16.71 1.87 * 16.71 18.02 1.31 *
physical 4.75 6.13 1.38 * 4.63 5.25 0.62 * 5.38 5.5 0.12 5.13 5.5 0.37 * 5 5.5 0.5 *
social 4.25 4.5 0.25 * 5.5 5.5 0 6.25 6.25 0 5 5.5 0.5 * 6 6.5 0.5 *
psychological 5.29 5.29 0 6 5.86 −0.14 7 5.86 −1.14 4.71 5.71 1 * 5.71 6.02 0.31
Cough VAS (mm) 30 26 −4 * 22 24 2 17 32 15 10 8 −2 74 58 −16 *
Cough No. 3 4 1 9 7 −2 7 8 1 3 3 0 6 6 0
Case 6 7 8 9 10
J-LCQ
total 18.92 16.81 −2.11 17.95 17.52 −0.43 19.59 20.5 0.91 8.32 12.96 4.64 * 16.2 20.63 4.43 *
physical 6.13 5.63 −0.5 5.63 5.38 −0.25 6.38 6.5 0.12 3.25 4 0.75 * 5.13 6.88 1.75 *
social 6.5 5.75 −0.75 5.75 6 0.25 * 6.5 7 0.5 * 2.5 4.25 1.75 * 5.5 6.75 1.25 *
psychological 6.29 5.43 −0.86 6.57 6.14 −0.43 6.71 7 0.29 2.57 4.71 2.14 * 5.57 7 1.43 *
Cough VAS (mm) 39 44 5 34 26 −8 18 30 12 52 31 −21 * 61 43 −18 *
Cough No. 7 7 0 4 4 0 2 9 7 * 3 4 1 5 4 −1
The mean MID of the J-LCQ corresponding to a small change in the four GRCQ score was 1.3.
The MIDs for domains were as follows: physical 0.2, social 0.2, and psychological 0.8.
A change in Δ cough scale by more than 15 mm was taken to be significant.
* Significant improvement in each MID of J-LCQ, Cough VAS after the low dose ITCZ therapy.
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the social domain (P < 0.05) and Δ cough scale (P <
0.05) between positive and negative results of immediate
skin test for B. adusta.
In this study, although the efficacy of ITCZ therapy
against SMIT was not estimated quantitatively, it was re-
markable that such complaints almost disappeared. Posi-
tive results for improvement of this SMIT were observed
in 6 patients in the BM colonization-positive group
(85.7%) and none in the BM colonization-negative group
(0%). There was a significant difference in the positive
ratio for improvement of this cough-related laryngeal
sensation between the two groups.
There were no significant differences in the change in
total score or in the domains of LCQ and Δ cough scale
between groups with positive and negative results for
sputum culture of BM fungi.Discussion
By focusing on the role of fungal colonization in
sensitization of patients with allergic fungal cough [9], it
has recently been demonstrated that colonization by B.
adusta is necessary in the process of sensitization to this
fungus [27]. Although the routine use of antifungal
drugs against fungus-sensitized asthma or severe asthma
with fungus sensitization [28] requires further evalu-
ation, in such cases of FACC or AFC, antifungal therapy
is expected to have advantages for reducing oreradicating the colonizing antigen and thus preventing
the sensitization process [9-12,29].
Although the presence of BM fungi in induced sputum
has been reported to be an important clinical finding
associated with CIC [13], at least three types of associ-
ation of BM fungi with CIC are possible: 1) sole
colonization with BM fungi; 2) sensitization with BM
fungi; and 3) colonization and/or sensitization by BM
fungi in addition to established CIC. It will be important
to perform prospective studies to evaluate both the ap-
propriate dose and period for performing ITCZ therapy
in a larger number of CIC patients in the near future.
Therefore, it does not seem to be a simple matter to ap-
propriately evaluate the efficacy of antifungal therapy for
CIC. A number of problems remain; what should the
target of anti-fungal therapy be? How should the efficacy
of the proposed antifungal drug be evaluated? The goal
of cough therapy is generally considered to be complete
remission of cough symptoms. However, even if impos-
sible, it may be a well controlled-state with improvement
of cough threshold, cough severity, cough frequency, or
quality of life.
In this study, we investigated some important clinical
signs [12] or allergological findings to predict the efficacy
of antifungal therapy and to clarify some problems raised
in the process of evaluating the clinical efficacy of the pro-
posed antifungal drug, especially with regard to both
colonization by BM fungi and sensitization to B. adusta
[27]. The positive ratio of BM cultured from the sputa of
Ogawa et al. Cough 2013, 9:1 Page 6 of 7
http://www.coughjournal.com/content/9/1/17 CIC patients (70.0%) in the present study was as high as
that reported previously (62.5%) [13]. This result recon-
firmed the importance of the presence of BM fungi in
induced sputum of CIC. The positive high ratio of both
skin reaction and LST against B. adusta suggested signifi-
cant correlations with sensitization to this fungus and CIC
patients.
B. adusta causes “Yakeirotake cough” [11], and has
attracted attention because of its potential role in increas-
ing the severity of cough symptoms in FACC patients by
sensitization to this fungus. Sautour et al. reported that in
outdoor samples, B. adusta (8%) was the third most fre-
quent species, especially in summer, and was the third and
fourth most common species in the adult hematology unit
(13%) and the pediatric hematology unit (11%), respect-
ively, at a French hospital [30]. They also mentioned that
the concentration of this fungus was particularly high dur-
ing the winter 2006/07, with a percentage close to 30% in
indoor samples. B. adusta is a wood decay BM fungus
with a worldwide distribution [31] and therefore this fun-
gal antigen may be a matter of clinical concern.
Based on the mean MID [26] of the J-LCQ [25], the effi-
cacy of low-dose ITCZ therapy was demonstrated in 5
patients. Although the MID may not always reflect suffi-
cient improvement of patient’s cough symptoms, it is true
that there were significant changes in Cough VAS in 3 of
the 5 patients. Therefore, these results do not exclude the
possibility of future research on the efficacy of ITCZ ther-
apy in CIC patients. It is also remarkable that changes in
Cough VAS were correlated with changes in domains in
the J-LCQ.
Despite investigating the allergological pattern with re-
gard to fungal sensitization, none of the allergological
findings except positive results for immediate cutaneous
reaction against B. adusta demonstrated significant corre-
lations with changes in cough VAS or J-LCQ. Appropriate
allergological findings, from the aspect of sensitization of
B. adusta, may lead to success in predicting the efficacy of
antifungal therapy in CIC patients.
Although the clinical manifestation, which is repre-
sented as a sensation of mucus in the throat [12], has been
believed to be an important cough-related laryngeal sensa-
tion, it was shown to be correlated with colonization by
BM fungi. This small but important symptom may have
been overlooked because the symptom is not picked up or
reflected even with use of capsaicin cough tests, cough
VAS, or LCQ; nevertheless, this symptom and cough itself
should also be treated.
Conclusions
At present, it is not possible to conclude whether ITCZ
therapy provides sufficient relief in CIC patients. However,
this study suggested both the possible applicability of low-
dose ITCZ therapy for treatment of CIC patients withregard to BM allergy and the necessity of development of
a new assessment questionnaire for cough-related laryn-
geal sensations.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
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